Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.
about
Kras(G12D) and Nkx2-1 haploinsufficiency induce mucinous adenocarcinoma of the lungWNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasisNanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphomaIntratumoral epiregulin is a marker of advanced disease in non-small cell lung cancer patients and confers invasive properties on EGFR-mutant cellsMolecular biology of lung cancer: clinical implicationsLung cancer signatures in plasma based on proteome profiling of mouse tumor modelsMutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomasNew molecularly targeted therapies for lung cancerA decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectivesPreclinical Murine Models for Lung Cancer: Clinical Trial ApplicationsReview of the current targeted therapies for non-small-cell lung cancerDevelopment of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitorsStructural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung CancerDiscovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC.AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancerEpiregulin is required for lung tumor promotion in a murine two-stage carcinogenesis model.NF-κB-activating complex engaged in response to EGFR oncogene inhibition drives tumor cell survival and residual disease in lung cancerCell type specificity of female lung cancer associated with sulfur dioxide from air pollutants in Taiwan: an ecological studyNovel insights into the molecular origins and treatment of lung cancerTERT Polymorphism rs2736100-C Is Associated with EGFR Mutation-Positive Non-Small Cell Lung CancerGefitinib-induced killing of NSCLC cell lines expressing mutant EGFR requires BIM and can be enhanced by BH3 mimeticsAKT1E¹⁷K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung CancerBIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutationsDetection of mutations in EGFR in circulating lung-cancer cellsThe role of epidermal growth factor receptor (EGFR) signaling in SARS coronavirus-induced pulmonary fibrosis.Api6/AIM/Spα/CD5L overexpression in alveolar type II epithelial cells induces spontaneous lung adenocarcinomaWhy do cancer cells become "addicted" to oncogenic epidermal growth factor receptor?Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations.Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas.Customized treatment in non-small-cell lung cancer based on EGFR mutations and BRCA1 mRNA expression.Inhibition of Hsp90 down-regulates mutant epidermal growth factor receptor (EGFR) expression and sensitizes EGFR mutant tumors to paclitaxel.Reduced NF1 expression confers resistance to EGFR inhibition in lung cancerERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics.Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitorsEvidence for self-renewing lung cancer stem cells and their implications in tumor initiation, progression, and targeted therapy.Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutationGuidelines for the welfare and use of animals in cancer research.Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations.Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M.DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma.
P2860
Q24303485-E69DDB86-1BB3-4E49-BE57-A8881E677475Q24310644-812DC57C-2C3C-488E-9E7A-0874E3B44C69Q24595213-9A886581-9466-4C3E-A2F0-33BD10E16735Q24603941-D23CB947-0907-485C-8709-A0015B040AD9Q24610335-A2C56D78-C486-42E3-8347-C4EA8C3343B0Q24628852-82936D12-9A8C-4DE2-922E-17621023C1C1Q24669579-DA609620-A03A-4DF4-B6DA-25EE58B9B6E7Q24680988-8F6EACFE-4F02-46BE-A1DA-AC6257B1A23DQ26797297-ACEF74CB-C711-43CC-9026-6CF9C502FDF1Q26863474-2357EF3D-F23D-432F-A106-6FA1339DABFAQ27015079-A7D63097-D885-4984-B154-E4C4A5BB9B3FQ27302811-77928921-B448-4AFD-A108-C633DB7F95C4Q27680966-3CE1F3C7-E0C5-4C34-81B9-20BDB083F423Q27852553-F37F2C41-C5CA-4F3F-B7AA-4F10D5355E4CQ27853013-63F6FE54-E7BD-4C1B-9D99-78E2C85F693FQ27853346-D3E7D5D2-B7BB-4FF6-A22C-84D62E61E272Q28259999-2BDDCE89-39C5-4A7F-A95C-619198021E39Q28386411-C0C2E4F4-82C1-4365-BA87-B32F66004E27Q28386773-8DEDDEEF-E982-4266-8C67-B5C7499E3B5BQ28393844-EBE272C9-E465-4D8B-AF86-204484A9309CQ28469345-0F3F4434-F4C1-4871-8114-BA9D68D33741Q28550038-F641C859-4309-4BCB-A42C-2240AA308BF6Q28756824-47A15BA2-94B7-4497-89C0-E7EF7EBCF569Q29615033-515D4521-DD88-40E6-826F-EDEA0A04DAF5Q30234893-9FC00F71-0BA6-483A-B805-EF883A27F9F7Q30503504-715A5BEA-4439-48CD-8CD2-6DEF1E62237DQ33304557-472077E1-2711-4780-8BA2-0B5F4E79ED89Q33306709-88251A5C-664C-49D1-A5A3-DE92B1CEE6D6Q33332189-A2AB5F8F-DD33-4198-8878-33B76047F86FQ33438894-39817D3D-2C3B-4C2C-B22C-FCFFF4B08D57Q33571026-86F2C675-06EF-4D93-A864-A7DF0C67537CQ33572728-3C2784F4-5D0F-451F-B84E-D6BF535108CDQ33601653-92CC74BC-71FE-4B35-91B6-6F05790D1BEDQ33769838-8CC375E9-252D-4E85-B3DB-E72778ED76CFQ33829820-1938859A-2B5C-46B1-BAA4-A28268DA4B15Q33902463-5F7FAC04-28E2-4E86-8B2E-6B89BAF0A9D3Q33903753-3D124D03-AFB9-4285-984C-648102358502Q33945734-63755DA6-E57B-4EAB-AE99-CC0BF617D1DEQ33948614-C78601CD-D4A3-4A4D-A261-0D8F574FFEA1Q33952447-98CBFCD6-49F8-4B5F-B8B9-10CF9E0D9BCA
P2860
Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Lung adenocarcinomas induced i ...... n-regulation of the receptors.
@ast
Lung adenocarcinomas induced i ...... n-regulation of the receptors.
@en
Lung adenocarcinomas induced i ...... n-regulation of the receptors.
@nl
type
label
Lung adenocarcinomas induced i ...... n-regulation of the receptors.
@ast
Lung adenocarcinomas induced i ...... n-regulation of the receptors.
@en
Lung adenocarcinomas induced i ...... n-regulation of the receptors.
@nl
prefLabel
Lung adenocarcinomas induced i ...... n-regulation of the receptors.
@ast
Lung adenocarcinomas induced i ...... n-regulation of the receptors.
@en
Lung adenocarcinomas induced i ...... n-regulation of the receptors.
@nl
P2093
P2860
P50
P356
P1433
P1476
Lung adenocarcinomas induced i ...... n-regulation of the receptors.
@en
P2093
Emily A Schonfeld
Maureen F Zakowski
Pang-Dian Fan
P2860
P304
P356
10.1101/GAD.1417406
P577
2006-05-16T00:00:00Z